Novartis licenses ophthalmology gene therapy from Spark Therapeutics – Zenopa
Zacks.com |
Novartis licenses ophthalmology gene therapy from Spark Therapeutics
Zenopa Novartis has agreed an exclusive licensing deal for an innovative ophthalmology gene therapy from Spark Therapeutics. The deal covers development, registration and commercialisation rights to voretigene neparvovec – which is sold in the US under the … Bio Roundup: Spark v. ICER, A Solid Revelation, T Cell Deals & MoreXconomy Novartis Gets Spark Therapeutics’ Luxterna License Outside USNasdaq |
|
What Good Is Crispr If It Can’t Get Where It Needs to Go?
WIRED The first US trials of Crispr safety are set to begin any day now, with Europe expected to follow later this year. Chinese scientists, meanwhile, have been testing Crispr humans since 2015, as the Wall Street Journal recently reported, with mixed … |
WIRED |
What Good Is Crispr If It Can’t Get Where It Needs to Go?
WIRED The first US trials of Crispr safety are set to begin any day now, with Europe expected to follow later this year. Chinese scientists, meanwhile, have been testing Crispr humans since 2015, as the Wall Street Journal recently reported, with mixed … The US Government Hopes $236 Million Will Make Gene Editing MainstreamGizmodo Australia |
|
Gene Therapy: Pipeline of Possibilities but Challenges for Pricing
Lexology One of the therapeutic areas in development that represents the greatest scientific promise is gene therapy. Gene therapy’s potential is particularly exciting in the possibilities it holds for transforming and curing debilitating diseases that, in some … |